Europe Boosts Peptide Output As AI Reshapes R&D

Manufacturers expand capacity for GLP-1 drugs while digital tools gain ground in discovery and early development

18 Feb 2026

Europe’s peptide manufacturers are expanding production capacity as global demand for obesity and metabolic treatments rises, strengthening the region’s position in the supply of peptide active pharmaceutical ingredients.

Companies including Switzerland’s Bachem have announced site expansions to meet growing orders linked to GLP-1 therapies and other peptide-based medicines. Across Germany and other parts of the continent, contract development and manufacturing organisations are adding synthesis lines, upgrading purification systems and reinforcing supply chains to support commercial-scale output.

The investment reflects sustained demand for high-value peptide APIs and pressure from pharmaceutical clients to ensure reliable supply. The recent success of GLP-1 drugs has intensified competition for manufacturing capacity, prompting producers to accelerate capital spending.

Solid-phase peptide synthesis remains the backbone of industrial production. Improvements in automation have increased reproducibility and scale, helping companies move more smoothly from clinical batches to full commercial volumes. Equipment upgrades and tighter process controls are also improving consistency, particularly as peptide chains become longer and regulatory requirements more stringent.

While manufacturing expansion is largely physical, the most significant technological change is taking place upstream in research and early development. Artificial intelligence tools are being used to predict peptide structure, stability and biological activity, allowing researchers to narrow candidate lists more quickly. Generative design platforms and sequence optimisation software enable scientists to explore wider chemical possibilities while reducing the number of laboratory experiments required.

Digital systems are also playing a growing role in early process development. By analysing experimental data, machine learning models can identify patterns and guide trial design, potentially shortening development timelines. However, fully autonomous AI directed manufacturing remains uncommon in regulated commercial settings.

Instead, companies are investing in stronger data infrastructure to improve analytics, documentation and compliance. Industry executives say the ability to combine scalable chemistry with robust digital systems will be central to maintaining Europe’s competitiveness.

As demand for peptide medicines continues to expand, the sector’s long term position is likely to depend not only on capacity growth but also on how effectively producers integrate data driven tools into development and quality systems.